I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Genetic Testing for Inherited Retinal Diseases
Understanding Inherited Retinal Diseases
Inherited retinal diseases, often called IRDs, are conditions caused by gene mutations that disrupt the normal function of the retina. Understanding what these diseases are and how they develop helps patients make sense of their diagnosis and the options available to them.
IRDs are a broad family of conditions in which a defect in one or more genes causes the retina's light-sensing cells to deteriorate over time. The retina is a thin layer of tissue at the back of the eye that captures light and converts it into electrical signals sent to the brain as vision. When a gene critical to retinal health is not functioning correctly, that process is disrupted in ways that often worsen gradually.
IRDs are considered rare diseases, but as a group they affect a meaningful number of people worldwide. Despite being individually uncommon, hundreds of distinct genes are known to cause different forms of inherited retinal disease. Most IRDs are monogenic, meaning a change in just one gene is sufficient to cause the condition. This makes precise genetic identification both possible and clinically important.
Several well-recognized conditions fall under the category of IRDs. Each one affects the retina in a distinct way, progresses at its own pace, and involves different genes.
- Retinitis pigmentosa (RP): The most common IRD, affecting approximately one in 4,500 people. It causes progressive loss of peripheral (side) vision and night vision, often beginning in young adulthood.
- Stargardt disease: Affects roughly one in 17,000 people. It primarily damages central vision, making tasks such as reading and recognizing faces increasingly difficult.
- Usher syndrome: Occurs in approximately one in 25,000 people. It causes both progressive vision loss from RP and hearing loss, making it a complex condition to manage.
- Leber congenital amaurosis (LCA): Affects approximately one in 42,000 people. It is one of the earliest-presenting IRDs, often causing severe visual impairment from infancy.
- Choroideremia: A condition primarily affecting males that leads to gradual loss of the choroid (the layer of blood vessels beneath the retina), the retinal pigment epithelium, and the photoreceptor cells.
Because dozens of distinct conditions fall under this umbrella, accurate diagnosis requires both a thorough clinical evaluation and genetic testing to identify the specific underlying cause.
Inherited retinal diseases can be passed from parent to child through several different inheritance patterns, depending on the specific gene involved and how that gene behaves in the body.
In autosomal dominant inheritance, a mutation in just one copy of the gene is enough to cause the disease. In autosomal recessive inheritance, a child must inherit a mutated copy from each parent. Carriers of autosomal recessive conditions often have no symptoms themselves but can pass the mutation to their children without knowing it. In X-linked inheritance, the altered gene sits on the X chromosome, which is why these conditions primarily affect males. A significant number of otherwise healthy individuals carry at least one IRD-related gene mutation without any symptoms, which is one reason genetic counseling is so valuable for families navigating these diagnoses.
Recognizing Signs and Symptoms
IRDs can appear at any stage of life, from infancy through adulthood. Recognizing early changes is important because timely evaluation leads to more options for monitoring, treatment, and family planning.
Some inherited retinal diseases become apparent very early in life. Parents of infants with Leber congenital amaurosis may notice that their baby does not track objects with their eyes or respond normally to visual stimuli. A child with this condition may also repeatedly rub or press on their eyes, a behavior known as the oculodigital sign. This occurs because direct pressure on the eye stimulates the remaining photoreceptor cells, creating a brief visual sensation.
X-linked retinoschisis, a condition that affects the structural layers of the retina, is typically identified in young males from infancy through school age. Signs can include crossed eyes (strabismus), involuntary eye movements (nystagmus), and reduced vision. When vision loss is mild, it may not become apparent until a child fails a routine school vision screening, which is one reason regular eye examinations in childhood matter so much.
Many inherited retinal diseases, particularly retinitis pigmentosa, develop gradually and may not cause noticeable symptoms for years. Early signs often include difficulty seeing in dim lighting, a problem commonly known as night blindness. As the condition progresses, the visual field may narrow, producing a tunnel vision effect as peripheral sight slowly fades. Central vision can remain relatively preserved for many years before it too becomes affected.
Stargardt disease often first appears in childhood or early adulthood and primarily affects central vision. A person may notice blurry or distorted vision when reading, difficulty recognizing faces even at close range, or a gradual reduction in the ability to see fine detail. These symptoms can meaningfully affect daily life even when peripheral vision and the ability to move around independently remain intact.
Any unexplained or progressive change in vision should be evaluated by a retina specialist. Symptoms that warrant prompt attention include increasing difficulty seeing at night, loss of peripheral vision, blurry or distorted central vision, and unusual sensitivity to light. These changes can begin subtly, which is why many people delay seeking care longer than they should.
In children, signs such as poor visual tracking, repeated eye rubbing, abnormal eye movements, crossed eyes, or a failed school vision screening are all reasons to arrange a thorough examination. Early diagnosis through genetic testing can help determine whether an approved treatment or clinical trial may be appropriate, and it gives families the information they need to plan ahead.
Diagnosing Inherited Retinal Diseases
Diagnosis of an IRD involves two complementary steps: a detailed clinical examination of the retina followed by genetic testing to identify the specific mutation responsible. Together, these tools provide the clearest possible picture of what is happening in the retina and why.
The diagnostic process begins with a comprehensive examination by a retina specialist. Using specialized imaging and functional tests, the specialist can assess the structure and activity of the retina in detail.
Optical coherence tomography (OCT) creates high-resolution cross-sectional images of the retinal layers without touching the eye, allowing the specialist to detect even subtle structural changes. Electroretinography (ERG) measures the electrical responses of the retina's light-sensing cells to reveal how well those cells are functioning. Wide-field fundus imaging captures a broader view of the peripheral retina, which is often affected early in conditions like retinitis pigmentosa. These tools help establish a clinical diagnosis and guide the selection of genetic tests, but they cannot identify the specific gene responsible. That requires laboratory analysis of the patient's DNA.
Genetic testing analyzes a person's DNA to identify mutations in the genes associated with inherited retinal diseases. The sample needed is simple to collect, either a blood draw or a saliva sample collected in a tube. That sample is sent to a specialized genetics laboratory where the DNA is extracted, processed, and analyzed using advanced sequencing technology.
Most modern genetic testing for IRDs uses a method called next-generation sequencing (NGS), which reads many segments of DNA simultaneously and compares the results to a reference map of the human genome. The laboratory then evaluates any differences found to determine whether they are likely responsible for the retinal condition. Results are typically returned within several weeks and are reviewed in the context of the patient's clinical findings.
The type of genetic test recommended depends on the individual's clinical presentation, family history, and the suspected diagnosis. There are three main approaches used for IRD testing today.
- Targeted gene panel sequencing: Analyzes a specific set of genes known to cause inherited retinal diseases. Current panels typically include 269 or more IRD-related genes and are often the appropriate starting point for most patients.
- Whole exome sequencing: Examines all the protein-coding regions of the genome, extending beyond the genes on standard panels. This can sometimes uncover mutations in genes not yet included in targeted panels.
- Whole genome sequencing: The most comprehensive option available. It sequences virtually all of a person's DNA, including non-coding regions that the other two methods may not cover, and can detect a broader range of mutation types.
Your retina specialist will discuss which type of testing is most appropriate based on your specific clinical picture and the results of your eye examination.
Panel-based next-generation sequencing identifies a causative mutation in approximately 60 to 70 percent of cases, according to the American Academy of Ophthalmology. This is a meaningful rate of detection, but it also means that some patients will not receive a definitive genetic answer from their first test.
An inconclusive or negative result does not mean the disease is not genetic in origin. The responsible mutation may lie in a region of DNA that current technology has difficulty analyzing, or it may involve a gene not yet recognized as a cause of retinal disease. As sequencing technology continues to improve and scientific knowledge of IRD genetics grows, patients who received inconclusive results in the past may benefit from retesting with newer methods. A retina specialist or genetic counselor can advise on when retesting may be appropriate.
The Role of Genetic Counseling
Genetic counseling is a critical part of the testing process. It helps patients and their families move from having genetic data to truly understanding what that data means for their health, their family members, and their future decisions.
A genetic counselor is a trained healthcare professional who specializes in interpreting genetic test results and explaining their implications. After testing, the counselor will review the inheritance pattern of the identified gene mutation, clarify the likelihood that siblings, parents, or children may be affected or carry the mutation, and explain what the findings may mean for future generations.
The American Academy of Ophthalmology supports genetic testing for patients with a suspected genetically caused retinal degeneration and highlights the benefit of evaluation for at-risk family members. Genetic counseling bridges the gap between complex laboratory findings and the practical decisions families need to make. It can also provide meaningful emotional support to patients navigating a new or evolving diagnosis.
Genetic counseling is available through academic medical centers, specialized retinal practices, and through telemedicine platforms. Virtual genetic counseling services have expanded access significantly, making it easier for patients in many locations to connect with counselors who specialize in ocular genetics without traveling long distances.
A retina specialist can provide a referral to a genetic counselor with experience in inherited retinal diseases. Pre-test counseling helps set realistic expectations about what results may look like, while post-test counseling is essential for fully understanding findings and determining appropriate next steps for the patient and their family.
Treatment Options and Gene Therapy
While not every form of inherited retinal disease has an approved treatment today, the therapeutic landscape is changing. Genetic testing plays a direct role in determining which patients qualify for existing therapies and which may benefit from emerging options in clinical trials.
In 2017, the U.S. Food and Drug Administration approved the first gene therapy for an inherited retinal disease. This treatment is designed for patients with vision loss caused by mutations in both copies of the RPE65 gene. It works by delivering a functional copy of that gene directly into retinal cells through a surgical injection, allowing those cells to produce a protein they were previously unable to make.
Genetic testing is required to confirm RPE65 mutations before this therapy can be offered. Without a confirmed genetic result, eligibility cannot be established. The approval of this therapy was a landmark moment in retinal medicine and clearly illustrated why genetic testing matters: the same clinical appearance can have different underlying genetic causes, and only a confirmed result can unlock access to treatments tied to specific mutations.
Research into gene-based therapies for inherited retinal diseases is a rapidly advancing area of ophthalmology. Numerous clinical trials are currently studying treatments for conditions including choroideremia, X-linked retinitis pigmentosa, Stargardt disease, and achromatopsia (a condition affecting color vision and light sensitivity). Some trials use gene replacement strategies, while others investigate gene editing techniques that aim to repair the mutation directly within the cell.
Eligibility for most clinical trials requires a confirmed mutation in the specific gene being targeted. Patients who have already completed genetic testing and received a confirmed result are in a much stronger position to explore whether an ongoing study may apply to them. A retina specialist can review current trial options in the context of a patient's specific genetic diagnosis and help them understand what participation might involve.
For the many forms of IRD that do not yet have an approved gene therapy, supportive and rehabilitative care plays an important role in maintaining quality of life. Regular monitoring by a retina specialist allows for early detection of any meaningful changes in retinal structure or function. Low vision aids including optical magnifiers, high-contrast reading materials, and digital assistive technology can help patients maintain independence in daily activities.
Orientation and mobility training helps people adapt to changes in their visual field, while vocational rehabilitation programs support patients in continuing to work and manage daily life. Protecting the eyes from excessive light exposure may also help preserve remaining vision in some conditions. While certain nutritional supplements have been studied in retinal disease, no supplement has been proven to stop the progression of an IRD. All care decisions are individualized and guided by your specific diagnosis and the judgment of your retina specialist.
Living With an Inherited Retinal Disease
A genetic diagnosis is not simply a label. It is information that empowers better decisions, more informed conversations with your care team, and a clearer path forward for you and the family members who may share your risk.
After a genetic diagnosis, regular follow-up with a retina specialist remains important throughout life. Using tools like OCT and functional testing, the specialist can track changes in retinal structure over time, detect any meaningful shifts early, and adjust your care plan accordingly. Ongoing monitoring also ensures that patients are made aware of new treatment options as they become available.
The rate of vision change varies considerably among IRDs. Some conditions progress slowly over many decades, while others may cause more rapid deterioration. Knowing your specific gene mutation helps your retina specialist provide a more personalized outlook and set realistic expectations about what to watch for and when.
A confirmed genetic result provides meaningful information for family planning. Couples who know their carrier status can work closely with a genetic counselor to understand the probability of passing the mutation to their children and to learn what options may be available to them. For some inheritance patterns, reproductive options such as preimplantation genetic testing used alongside in vitro fertilization may be possible. A genetic counselor can help navigate these personal decisions with both clinical expertise and sensitivity.
A diagnosis also helps individuals prepare practically for potential vision changes over time. Connecting early with vocational rehabilitation services, becoming familiar with assistive technology, and building adaptive skills can help people remain active and independent even as vision changes over the years ahead.
The science of inherited retinal diseases is advancing quickly. New disease-causing genes continue to be identified, testing methods are becoming more sensitive and comprehensive, and the number of therapies moving through clinical trials is growing steadily. Patients with a confirmed genetic diagnosis are best positioned to take advantage of these developments as they emerge.
Registering with clinical trial databases allows patients to stay informed about studies they may qualify for based on their specific mutation. Patient advocacy and research organizations including the Foundation Fighting Blindness, the National Eye Institute, and the American Academy of Ophthalmology provide regularly updated information on research progress and support programs for patients and families living with IRDs.
Frequently Asked Questions
The following answers address common questions patients bring to us about inherited retinal diseases and genetic testing, with practical guidance that goes beyond what the sections above cover.
Yes, and this is one of the most important points for patients who have already received an inconclusive result to understand. Genetic testing reflects what science and technology can detect at the time the test is performed. As researchers identify new IRD-causing genes and laboratory methods become more precise, mutations that were undetectable a few years ago may now be findable with newer approaches. If your initial result was inconclusive, staying in contact with a retina specialist or genetic counselor ensures you will be informed when retesting may be worthwhile. An inconclusive result today does not mean there will never be an answer.
No. Collecting the genetic sample requires only a blood draw or a saliva sample, with no eye involvement whatsoever. The clinical examination that accompanies the diagnostic process may include pupil dilation, which temporarily increases light sensitivity and blurs near vision for a few hours. Electroretinography, if used, involves placing electrodes near the eye but is well tolerated and non-invasive. The genetic sample collection itself is simple and comfortable for most patients, including children.
Not necessarily, and this is where the inheritance pattern of your specific mutation matters greatly. In autosomal recessive conditions, your child would need to inherit an altered gene copy from both parents to develop the disease. If your partner does not carry a mutation in the same gene, the child would likely be a carrier but not affected. In autosomal dominant conditions, the risk to each child is approximately 50 percent. X-linked conditions follow a different pattern depending on whether the carrier parent is the mother or the father. A genetic counselor can provide a specific, personalized risk estimate based on your mutation and family history, which is far more useful than general population statistics.
Yes, and the pipeline is active and growing. While the approved RPE65 gene therapy remains the only fully FDA-approved treatment of its kind for an inherited retinal disease, clinical trials are actively investigating gene-based therapies for a number of other IRDs, including choroideremia, X-linked retinitis pigmentosa, Stargardt disease, and achromatopsia. These therapies must pass rigorous safety and efficacy testing before they can be approved for general use. The pace of research offers real reason for optimism, and a retina specialist can review your specific genetic diagnosis and help you understand whether any currently enrolling studies may be a relevant option for you.
Coverage depends on your specific insurance plan, your diagnosis, and whether the test is ordered with a clear clinical indication. Many insurers provide coverage for genetic testing when ordered in the context of a diagnosed or suspected hereditary retinal condition. Some plans require prior authorization before testing can proceed, so contacting your insurance provider before the sample is collected can help you understand what your out-of-pocket costs may be. Many genetics laboratories also offer financial assistance programs or alternative payment options for patients whose insurance does not cover testing costs.
Specialized Retina Care Across Connecticut
If you or a family member has been referred for evaluation of a possible inherited retinal disease, or if unexplained vision changes have you concerned, we encourage you to reach out to New England Retina Associates. Our fellowship-trained retina specialists provide expert care across the full scope of inherited retinal disease, from genetic testing coordination and precise diagnosis to long-term monitoring and access to emerging treatments. We welcome self-referred patients, physician referrals, and urgent consultations at our Connecticut locations, and we are committed to supporting you with the expertise, thoroughness, and compassionate attention you deserve.
30 Years of Care & Commitment
